CCT - Crypto Currency Tracker logo CCT - Crypto Currency Tracker logo
CoinDesk 2025-10-02 14:03:26

Crypto Market Maker GSR to Acquire FINRA-Registered Broker-Dealer Equilibrium Capital Services

Cryptocurrency market maker GSR has signed an agreement to acquire Equilibrium Capital Services, a Portland-based broker-dealer registered with the SEC and a member of FINRA. The deal, which is still pending regulatory approval, marks a step toward expanding GSR’s regulated presence in the United States. GSR did not disclose the terms of the Equilibrium Capital deal in its press release. Equilibrium Capital’s registration allows it to provide brokerage services under U.S. securities laws. By bringing it under its umbrella, GSR expects to offer institutional clients a more direct route into digital assets while operating within established compliance frameworks. GSR executives framed the move as part of a longer-term strategy to deepen its institutional ties in the U.S. Xin Song, the firm’s CEO, said the acquisition reflects GSR’s commitment to serving both entrepreneurs and large investors who want regulated access to crypto markets. The acquisition comes as regulators continue to shape the rules governing digital assets in the U.S. For a firm like GSR — best known for its global market-making and liquidity services — having a broker-dealer license could open doors to products that fall under securities oversight. To manage the acquisition process, GSR engaged Compliance Exchange Group (CXG) for regulatory guidance and BrokerDealerForSale.com for the acquisition of Equilibrium Capital Services. GSR has been steadily building its regulated services portfolio. In recent months, the firm has expanded institutional access to tokenized real-world assets through a partnership with DigiFT, according to a press release. The market making firm also invested in Maverix Securities to support the development of regulated structured products, and led digital-asset treasury investment strategies for Nasdaq-listed companies, including MEI Pharma and Upexi.

阅读免责声明 : 此处提供的所有内容我们的网站,超链接网站,相关应用程序,论坛,博客,社交媒体帐户和其他平台(“网站”)仅供您提供一般信息,从第三方采购。 我们不对与我们的内容有任何形式的保证,包括但不限于准确性和更新性。 我们提供的内容中没有任何内容构成财务建议,法律建议或任何其他形式的建议,以满足您对任何目的的特定依赖。 任何使用或依赖我们的内容完全由您自行承担风险和自由裁量权。 在依赖它们之前,您应该进行自己的研究,审查,分析和验证我们的内容。 交易是一项高风险的活动,可能导致重大损失,因此请在做出任何决定之前咨询您的财务顾问。 我们网站上的任何内容均不构成招揽或要约